Evidence map›Paper›PMID 40828961›Full record

ArticleThe oncologist2025

Prognostic covariates associated with outcomes in patients with NPM1-mutated acute myeloid leukemia.

Shunjie Yu, Sen Yang, Lijuan Hu, Wenbing Duan, Ting Zhao, GuoRui Ruan, Yazhen Qin, Yazhe Wang, Yueyun Lai, Hongxia Shi and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Shunjie YuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Sen YangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Lijuan HuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Wenbing DuanPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Ting ZhaoPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
GuoRui RuanPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Yazhen QinPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Yazhe WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Yueyun LaiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Hongxia ShiPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Feifei TangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Yuqian SunPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Jinsong JiaPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Jing WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Qiang FuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Hao JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Lanping XuPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Yu WangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Xiaohui ZhangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.
Xiaojun HuangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.ORCID 0000-0002-2145-6643
Qian JiangPeking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University, Beijing 100044, China.ORCID 0000-0001-7131-0522

Funding

National Natural Science Foundation of China No. 81970140 and No.82370161
6 · The paper itself

Abstract

backgroundNPM1 mutacute myeloid leukemia (AML) patients have greater heterogeneity. However, data on the comprehensive integration of clinical and genetic data in NPM1mutAML patients are limited, especially in the FLT3 inhibitor era.

methodsData from consecutive AML patients with NPM1mut/FLT3-ITDwt (n = 203) and NPM1mut/FLT3-ITDmut (n = 115) were reviewed.

resultsIn NPM1mut/FLT3-ITDwt patients, in multivariate analyses male sex, WBC count ≥19 × 109/L, bone marrow blasts ≥ 70%, NPM1 non-A/B/D type mutation, TET2 mutation and measurable residual disease (MRD) positivity after the first cycle of consolidation were significantly-associated with poor relapse-free survival (RFS) and survival. Based on the adverse prognostic covariates, patients were classified into low-risk (score 0-2, n = 113, 64%), intermediate-risk (score 3, n = 43, 25%) and high-risk (score ≥4, n = 20, 11%) subgroups, with significant differences in 3-year probabilities of RFS and survival (all P values < .001). In NPM1mut/FLT3-ITDmut patients who did not undergo allogeneic hematopoietic stem cell transplantation (allo-HSCT) in CR1, single FLT3-ITD mutation, NPM1 non-A/B/D type mutation, TET2 mutation and MRD positivity after the first cycle of consolidation, poor RFS; platelet ≤60 × 109/L and albumin <40 g/L, poor survival. Patients were classified into low-risk (score 0-2) allo-HSCT (n = 9, 11%) or non-allo-HSCT (n = 26, 31%), and high-risk (score ≥ 3) allo-HSCT (n = 8, 10%) or non-allo-HSCT (n = 40, 48%). The first 3 subgroups had comparable outcomes, but were significantly superior to the high-risk non-allo-HSCT subgroup (all P values for trend = .001-.010).

conclusionsWe identified high-risk AML patients with NPM1mut/FLT3-ITDwt or NPM1mut/FLT3-ITDmut who might consider more intensive therapy.

Indexed as

Leukemia, Myeloid, AcuteMutationNuclear ProteinsAdolescentAdultAgedDioxygenasesFemalefms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationHumansMaleMiddle AgedNucleophosminPrognosisYoung AdultDioxygenasesFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNuclear ProteinsNucleophosminacute myeloid leukemiaFLT3-ITDmutation topographyNPM1survival prognosis

Identifiers

PMID40828961
PMCPMC12449623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.